Targeting the intracellular signaling "STOP" and "GO" pathways for the treatment of alcohol use disorders

被引:26
|
作者
Ron, Dorit [1 ]
Berger, Anthony [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
关键词
Alcohol; Addiction; Signaling; Translation; Medication Development; Fyn; mTOR; BDNF; GDNF; LONG-TERM POTENTIATION; NR2B-CONTAINING NMDA-RECEPTORS; CONDITIONED-PLACE PREFERENCE; ACTIVITY-DEPENDENT SECRETION; TYROSINE-PHOSPHATASE ALPHA; P75 NEUROTROPHIN RECEPTOR; DOPAMINE D-3 RECEPTOR; ANTI-ADDICTION DRUG; SYNAPTIC PLASTICITY; DORSOMEDIAL STRIATUM;
D O I
10.1007/s00213-018-4882-z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In recent years, research has identified the molecular and neural substrates underlying the transition of moderate "social" consumption of alcohol to the characteristic alcohol use disorder (AUD) phenotypes including excessive and compulsive alcohol use which we define in the review as the GO signaling pathways. In addition, growing evidence points to the existence of molecular mechanisms that keep alcohol consumption in check and that confer resilience for the development of AUD which we define herein as the STOP signaling pathways. In this review, we focus on examples of the GO and the STOP intracellular signaling pathways and discuss our current knowledge of how manipulations of these pathways may be used for the treatment of AUD.
引用
收藏
页码:1727 / 1743
页数:17
相关论文
共 50 条
  • [41] Motivation as a focus in the treatment of alcohol use disorders
    Afonso, H.
    Gomes, J.
    Lima, G.
    EUROPEAN PSYCHIATRY, 2019, 56 : S23 - S23
  • [42] Intracellular pathways of antipsychotic combined therapies: Implication for psychiatric disorders treatment
    de Bartolomeis, Andrea
    Avvisati, Livia
    Iasevoli, Felice
    Tomasetti, Carmine
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 718 (1-3) : 502 - 523
  • [43] GABAB receptor intracellular signaling: novel pathways for depressive disorder treatment?
    Korczak, Maciej
    Kurowski, Przemyslaw
    Lesniak, Anna
    Gronbladh, Alfhild
    Filipowska, Anna
    Bujalska-Zadrozny, Magdalena
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 885
  • [44] How does neuroimmune signaling impact alcohol use disorders?
    Guerri, C.
    Urena-Peralta, J.
    Pascual, M.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 46 : 39 - 40
  • [45] DEVELOPMENT OF NOVEL COMPOUNDS TARGETING LIGAND-GATED ION CHANNELS FOR THE TREATMENT OF ALCOHOL USE DISORDERS
    Davies, D. L.
    Asatryan, L.
    Arden, C. N.
    Ning, N.
    Yardley, M.
    Wyatt, L.
    Khoja, S.
    Louie, S. G.
    Alkana, R. L.
    Petasis, N. A.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2012, 36 : 132A - 132A
  • [46] On the Use of Cognitive Bias Modification in the Treatment of Alcohol Use Disorders
    Wiers, Reinout
    PHARMACOLOGICAL REPORTS, 2019, 71 (06) : 1316 - 1316
  • [47] The Use of Gabapentin for the Treatment of Alcohol and Tobacco Use Disorders: A Review
    Quintero Garzola, Gabriel C.
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2020, 12 : 43 - 60
  • [48] Calcineurin signaling as a target for the treatment of alcohol abuse and neuroinflammatory disorders
    Ronan, Patrick J.
    Flynn, Sarah A.
    Beresford, Thomas P.
    MOLECULAR BASIS OF NEUROPSYCHIATRIC DISORDERS: FROM BENCH TO BEDSIDE, 2019, 167 : 125 - 142
  • [49] Alcohol and substance use disorders: Algorithms and critical pathways for healthcare delivery
    Miller T.W.
    Suchinsky R.
    Leukefeld C.
    Kraus R.F.
    Journal of Contemporary Psychotherapy, 1997, 27 (3) : 189 - 200
  • [50] Molecular Signaling Pathways in the Hippocampus of Rhesus Monkeys With Chronic Alcohol Use
    Pareek, Tanya
    Platt, Donna
    Grant, Kathleen
    Gisabella, Barbara
    Pantazopoulos, Harry
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260